00:23:23 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandDanmark
ListaSpotlight DK
SektorHälsovård
IndustriMedicinteknik
Curasight är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom utveckling av teknologiska produkter. Produktportföljen är bred och fokuserar i stor grad utveckling av produkter inom området Positron Emissions Tomography (PET). Verksamheten drivs med störst närvaro inom Skandinavien. Curasight har sitt huvudkontor i Köpenhamn.

Kalender

2023-11-24 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-03-30 Årsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-24 Kvartalsrapport 2022-Q3
2022-08-25 Kvartalsrapport 2022-Q2
2022-05-24 Kvartalsrapport 2022-Q1
2022-04-27 Årsstämma 2022
2022-03-25 Ordinarie utdelning CURAS 0.00 DKK
2022-02-24 Bokslutskommuniké 2021
2021-11-25 Kvartalsrapport 2021-Q3
2021-08-24 Kvartalsrapport 2021-Q2
2021-06-01 Extra Bolagsstämma 2021
2021-05-20 Kvartalsrapport 2021-Q1
2021-03-26 Ordinarie utdelning CURAS 0.00 DKK
2021-03-25 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-11-30 Kvartalsrapport 2020-Q3
2022-08-25 07:00:00

Copenhagen, Denmark, 25 August 2022 - Curasight A/S ("Curasight" or the "Company" - TICKER: CURAS) hereby publishes the interim report for the period January 1 - June 30, 2022. The interim report is available as an attached file to this release and on the Company's website. Below is a summary of the report.

Curasight's CEO Ulrich Krasilnikoff comments:

"During the first half of 2022, we have actively worked on strengthening key values to accelerate Curasight's position as a theranostic company. I am thinking in particular of our recently expanded strategy, the granting of our US patent application relating to uTRACE[©] and the successful recruitment of the remaining patients to the investigator-initiated phase II study (uTRACE[©]) in brain cancer. Every day we continue to advance Curasight's technology, and I am convinced that we are on the right path toward our mission - to improve the lives of millions of people suffering from cancer."

 Q2 (April - June) 2022
  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -1,919,541 (-404,869) DKK
  • Profit/loss before taxes amounted to -2,876,062 (-1,079,213) DKK
  • Profit/loss for the period amounted to -2,243,328 (-841,783) DKK
  • Total assets amounted to 99,297,297 (60,860,495) DKK
  • Equity ratio amounted to 96,3 (94,4) %.
  • Earnings per share amounted to -0,11 (-0,05) DKK
H1 (January - June) 2022
  • Net sales amounted to 0 (0) DKK
  • Operating profit/loss amounted to -2,697,418 (-771,962) DKK
  • Profit/loss before taxes amounted to -4,492,362 (-2,076,728) DKK
  • Profit/loss for the period amounted to -3,504,042 (-1,619,848) DKK
  • Total assets amounted to 99,297,297 (60,860,495) DKK
  • Equity ratio amounted to 96,3 (94,4) %.
  • Earnings per share amounted to -0,17 (-0,09) DKK
Highlights during the first quarter
  • On April 22, Curasight announced that the United States Patent and Trademark Office has granted Curasight's United States Patent Application no. 16/870,776 is ready for allowance and the patent will be issued with patent no. 1131137.
  • On April 25, Ulrich Krasilnikoff and Andreas Kjær were invited and attended Sedermeradagen Stockholm. The presentation is available on Sedermeras Youtube channel.
  • On April 27, Curasight held an Annual General Meeting. Resolutions with summarized decisions are available on the company's website.
  • On May 18, Ulrich Krasilnikoff and Andreas Kjær gave an update on the company's strategy at Kapital Partner's Life Science Seminar.
  • On June 7, Curasight issued a total of 956,770 warrants for the purpose of launching the Company's long-term incentive program covering the Company's Board of Directors, Executive Management and other key employees.
  • On June 24, Curasight announced that a transaction with shares in Curasight A/S was made by managerial employee in the period 9 - 10 June 2022. Hanne Damgaard Jensen (Chief Development Officer) bought a total of 16.400 shares. Hanne Damgaard Jensen total holdings in Curasight A/S after the purchase of the shares is 20,000 shares.
  • On June 30, Curasight announced that the investigator-initiated phase II study using uPAR-PET in brain cancer had completed the inclusion of patients. First data from the study is expected to be published during H2 2022.
Highlights after the period
  • No other significant events have occurred since the end of the period that has materially affected this report.